PharVision Advisers »

Neuropace shares owned by PharVision Advisers

Quarter-by-quarter ownership of Neuropace (NPCE) shares owned by PharVision Advisers from 13F filings

Historical chart of PharVision Advisers investment in Neuropace

Tip: Access up to 7 years of quarterly data

All positions including Neuropace held by PharVision Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neuropace by PharVision Advisers

Quarter filed Position value Share count Share price at filing
2025-09-30 $232k 23k 10.31

More positions owned by PharVision Advisers

Wayfair Cl A (W)
ExlService Holdings (EXLS)
Up Fintech Hldg Sponsored Ads (TIGR)
Array Technologies Com Shs (ARRY)
Sprouts Fmrs Mkt (SFM)
Corporacion Amer Arpts S A (CAAP)
Vertiv Holdings Com Cl A (VRT)
Zevra Therapeutics Com New (ZVRA)
Bowhead Specialty Hldgs Com Shs (BOW)
Lexinfintech Hldgs Adr (LX)
Euronet Worldwide (EEFT)
Rigel Pharmaceuticals (RIGL)
Masimo Corporation (MASI)
LSB Industries (LXU)
Bright Horizons Fam Sol In D (BFAM)

View all positions for PharVision Advisers

Top funds holding Neuropace

Polar Capital Holdings
Soleus Capital Management
OrbiMed Advisors
Morgan Stanley
BlackRock
Vanguard Group
First Light Asset Management
Armistice Capital
Kent Lake PR
Driehaus Capital Management
Deutsche Bank Aktiengesellschaft
FMR
Geode Capital Management
State Street Corporation
Silvercrest Asset Management Group

View all funds holding Neuropace